433 related articles for article (PubMed ID: 33898959)
1. Potent suppression of hydrophobic bile acids by aldafermin, an FGF19 analogue, across metabolic and cholestatic liver diseases.
Sanyal AJ; Ling L; Beuers U; DePaoli AM; Lieu HD; Harrison SA; Hirschfield GM
JHEP Rep; 2021 Jun; 3(3):100255. PubMed ID: 33898959
[TBL] [Abstract][Full Text] [Related]
2. Pegbelfermin selectively reduces secondary bile acid concentrations in patients with non-alcoholic steatohepatitis.
Luo Y; Decato BE; Charles ED; Shevell DE; McNaney C; Shipkova P; Apfel A; Tirucherai GS; Sanyal AJ
JHEP Rep; 2022 Jan; 4(1):100392. PubMed ID: 34977519
[TBL] [Abstract][Full Text] [Related]
3. NASH-related increases in plasma bile acid levels depend on insulin resistance.
Grzych G; Chávez-Talavera O; Descat A; Thuillier D; Verrijken A; Kouach M; Legry V; Verkindt H; Raverdy V; Legendre B; Caiazzo R; Van Gaal L; Goossens JF; Paumelle R; Francque S; Pattou F; Haas JT; Tailleux A; Staels B
JHEP Rep; 2021 Apr; 3(2):100222. PubMed ID: 33615207
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients With Nonalcoholic Steatohepatitis.
Harrison SA; Neff G; Guy CD; Bashir MR; Paredes AH; Frias JP; Younes Z; Trotter JF; Gunn NT; Moussa SE; Kohli A; Nelson K; Gottwald M; Chang WCG; Yan AZ; DePaoli AM; Ling L; Lieu HD
Gastroenterology; 2021 Jan; 160(1):219-231.e1. PubMed ID: 32781086
[TBL] [Abstract][Full Text] [Related]
5. A Current Understanding of Bile Acids in Chronic Liver Disease.
Farooqui N; Elhence A; Shalimar
J Clin Exp Hepatol; 2022; 12(1):155-173. PubMed ID: 35068796
[TBL] [Abstract][Full Text] [Related]
6. [Characteristics and diagnostic value of serum bile acids profile in pregnant women with intrahepatic cholestasis of pregnancy and asymptomatic hypercholanemia of pregnancy].
Gou LS; Yin X; Liu J; Suo F; Wu XY; Wang ZZ; Wang QL; Dong BL; Gu MS; Liu DY
Zhonghua Fu Chan Ke Za Zhi; 2024 Apr; 59(4):270-278. PubMed ID: 38644273
[No Abstract] [Full Text] [Related]
7. Gender-Specific Bile Acid Profiles in Non-Alcoholic Fatty Liver Disease.
Fitzinger J; Rodriguez-Blanco G; Herrmann M; Borenich A; Stauber R; Aigner E; Mangge H
Nutrients; 2024 Jan; 16(2):. PubMed ID: 38257143
[TBL] [Abstract][Full Text] [Related]
8. The Commensal Microbe Veillonella as a Marker for Response to an FGF19 Analog in NASH.
Loomba R; Ling L; Dinh DM; DePaoli AM; Lieu HD; Harrison SA; Sanyal AJ
Hepatology; 2021 Jan; 73(1):126-143. PubMed ID: 32794259
[TBL] [Abstract][Full Text] [Related]
9. Bile acids contribute to the development of non-alcoholic steatohepatitis in mice.
Gillard J; Clerbaux LA; Nachit M; Sempoux C; Staels B; Bindels LB; Tailleux A; Leclercq IA
JHEP Rep; 2022 Jan; 4(1):100387. PubMed ID: 34825156
[TBL] [Abstract][Full Text] [Related]
10. Effect of NGM282, an FGF19 analogue, in primary sclerosing cholangitis: A multicenter, randomized, double-blind, placebo-controlled phase II trial.
Hirschfield GM; Chazouillères O; Drenth JP; Thorburn D; Harrison SA; Landis CS; Mayo MJ; Muir AJ; Trotter JF; Leeming DJ; Karsdal MA; Jaros MJ; Ling L; Kim KH; Rossi SJ; Somaratne RM; DePaoli AM; Beuers U
J Hepatol; 2019 Mar; 70(3):483-493. PubMed ID: 30414864
[TBL] [Abstract][Full Text] [Related]
11. Ablation of gut microbiota alleviates obesity-induced hepatic steatosis and glucose intolerance by modulating bile acid metabolism in hamsters.
Sun L; Pang Y; Wang X; Wu Q; Liu H; Liu B; Liu G; Ye M; Kong W; Jiang C
Acta Pharm Sin B; 2019 Jul; 9(4):702-710. PubMed ID: 31384531
[TBL] [Abstract][Full Text] [Related]
12. Bile acid profiles and mRNA abundance of bile acid-related genes in adipose tissue of dairy cows with high versus normal body condition.
Dicks L; Schuh-von Graevenitz K; Prehn C; Sadri H; Murani E; Ghaffari MH; Häussler S
J Dairy Sci; 2024 Mar; ():. PubMed ID: 38490538
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
Harrison SA; Ruane PJ; Freilich B; Neff G; Patil R; Behling C; Hu C; Shringarpure R; de Temple B; Fong E; Tillman EJ; Rolph T; Cheng A; Yale K
JHEP Rep; 2023 Jan; 5(1):100563. PubMed ID: 36644237
[TBL] [Abstract][Full Text] [Related]
14. Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial.
Brown EA; Minnich A; Sanyal AJ; Loomba R; Du S; Schwarz J; Ehman RL; Karsdal M; Leeming DJ; Cizza G; Charles ED
JHEP Rep; 2023 Apr; 5(4):100661. PubMed ID: 36866389
[TBL] [Abstract][Full Text] [Related]
15. The value of bile acid spectrum in the evaluation of hepatic injury in children with infectious mononucleosis caused by Epstein Barr virus infection.
Shen R; Zhou Y; Zhang L; Yang S
Front Pediatr; 2023; 11():1109762. PubMed ID: 37025296
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of aldafermin in non-alcoholic steatohepatitis: A systematic review and meta-analysis of randomized controlled trials.
Marey MM; Belal M; Awad AA; Rabea EM; Hassan MA; Abbas AW; Nashwan AJ
Clin Res Hepatol Gastroenterol; 2024 Jun; 48(6):102357. PubMed ID: 38688423
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
18. Characterization of conjugated and unconjugated bile acid transport via human organic solute transporter α/β.
Suga T; Yamaguchi H; Ogura J; Mano N
Biochim Biophys Acta Biomembr; 2019 May; 1861(5):1023-1029. PubMed ID: 30853579
[TBL] [Abstract][Full Text] [Related]
19. Circulating bile acids in healthy adults respond differently to a dietary pattern characterized by whole grains, legumes and fruits and vegetables compared to a diet high in refined grains and added sugars: A randomized, controlled, crossover feeding study.
Ginos BNR; Navarro SL; Schwarz Y; Gu H; Wang D; Randolph TW; Shojaie A; Hullar MAJ; Lampe PD; Kratz M; Neuhouser ML; Raftery D; Lampe JW
Metabolism; 2018 Jun; 83():197-204. PubMed ID: 29458053
[TBL] [Abstract][Full Text] [Related]
20. Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): a randomised, double-blind, placebo-controlled, phase 2b trial.
Harrison SA; Abdelmalek MF; Neff G; Gunn N; Guy CD; Alkhouri N; Bashir MR; Freilich B; Kohli A; Khazanchi A; Sheikh MY; Leibowitz M; Rinella ME; Siddiqui MS; Kipnes M; Moussa SE; Younes ZH; Bansal M; Baum SJ; Borg B; Ruane PJ; Thuluvath PJ; Gottwald M; Khan M; Chen C; Melchor-Khan L; Chang W; DePaoli AM; Ling L; Lieu HD
Lancet Gastroenterol Hepatol; 2022 Jul; 7(7):603-616. PubMed ID: 35325622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
